Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Biol Ther ; 19(1): 63-75, 2018 01 02.
Article in English | MEDLINE | ID: mdl-29053388

ABSTRACT

Colorectal cancer (CRC) is the second leading cause of death among cancer patients in the Northern countries. CRC can reappear a long time after treatment. Recent clinical studies demonstrated that, in response to chemotherapy, cancer cells may undergo stress-induced premature senescence (SIPS), which typically results in growth arrest. Nonetheless, these senescent cells were reported to divide in an atypical manner and thus contribute to cancer re-growth. Therefore, we examined if SIPS escape may follow treatment with chemotherapeutics used clinically: 5-fluorouracil (5-FU), oxaliplatin (OXA) and irinotecan (IRINO). To mimic the therapeutic regimes we exposed human colon cancer HCT116 and SW480 cells to repeated cycles of drug treatment. The cells treated with 5-FU or IRINO exhibited several hallmarks of SIPS: growth arrest, increased size and granularity, polyploidization, augmented activity of the SA-ß-galactosidase, accumulation of P21 and CYCLIN D1 proteins, and the senescence-associated secretory phenotype. Moreover, re-population of the cancer cell cultures was delayed upon treatment with the senescence-inducing agents. At the same time, we detected a subpopulation of senescent colon cancer cells with features of stemness: elevated NANOG expression, exclusion of Hoechst 33342 (typical for side population) and increased CD24 expression. Additionally, rare, polyploid cells exhibited blastocyst-like morphology and produced progeny. In parallel, majority of chemotherapeutics-treated cells underwent mesenchymal to epithelial transition, as the percentage of CD44-positve cells was reduced, and levels of E-cadherin (epithelial marker) were elevated. Our study demonstrates that a subpopulation of chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features. This may contribute to their resistance to chemotherapy and their ability to re-grow cancer after completion of therapeutic intervention.


Subject(s)
Antineoplastic Agents/pharmacology , Cellular Senescence/drug effects , Colonic Neoplasms/drug therapy , Epithelial-Mesenchymal Transition/drug effects , Neoplastic Stem Cells/drug effects , Antineoplastic Agents/therapeutic use , Colonic Neoplasms/pathology , Cyclin D1/metabolism , Drug Resistance, Neoplasm/drug effects , Fluorouracil/pharmacology , Fluorouracil/therapeutic use , HCT116 Cells , Humans , Hyaluronan Receptors/metabolism , Irinotecan/pharmacology , Irinotecan/therapeutic use , Neoplastic Stem Cells/pathology , Oxaliplatin/pharmacology , Oxaliplatin/therapeutic use
2.
J Physiol Pharmacol ; 60(2): 3-12, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19617639

ABSTRACT

OBJECTIVE: It was reported that some effects of pentoxifylline (PTX) are mediated by heme oxygenase-1 (HO-1) induction. We investigated the role of HO-1 in anti-inflammatory activity of PTX. METHODS: Experiments were performed in human and murine monocytes and endothelial cells and in HO-1 deficient mice. RESULTS: PTX dose-dependently decreased expression of HO-1 in cell lines studied. As expected, PTX reduced also production of TNF. This effect was independent of HO-1 activity, as demonstrated in cells treated with HO-1 activators and inhibitors or in cells overexpressing HO-1. Moreover, inhibition of TNF was the same in human endothelial cells of different HO-1 genotypes, showing that PTX is similarly efficient in carriers of more and less active HO-1 promoter variants. In mice, PTX did not influence HO-1 expression, as measured in liver, kidney, spleen, heart, and skin. Accordingly, the response of PTX treated animals to LPS was the same in wild type and HO-1 deficient mice. PTX to a similar extent increased influx of leukocyte into peritoneal cavity, decreased production of TNF and reduced expression of VCAM-1 in vascular intima. CONCLUSION: PTX inhibits production of TNF and may decrease inflammatory reaction both in vitro and in vivo, but these effects are independent of HO-1.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Heme Oxygenase-1/metabolism , Pentoxifylline/pharmacology , Phosphodiesterase Inhibitors/pharmacology , Animals , Cell Line , Dose-Response Relationship, Drug , Endothelial Cells/drug effects , Endothelial Cells/metabolism , Endothelium, Vascular/cytology , Endotoxemia/drug therapy , Endotoxemia/metabolism , Heme Oxygenase-1/genetics , Humans , Lipopolysaccharides/pharmacology , Mice , Mice, Inbred C57BL , Mice, Knockout , Monocytes/drug effects , Monocytes/metabolism , Polymorphism, Genetic , Signal Transduction/drug effects , Tumor Necrosis Factor-alpha/biosynthesis , Vascular Cell Adhesion Molecule-1/genetics , Vascular Cell Adhesion Molecule-1/metabolism
3.
Oncogene ; 25(24): 3365-74, 2006 Jun 08.
Article in English | MEDLINE | ID: mdl-16462769

ABSTRACT

Photodynamic therapy is a promising antitumor treatment modality approved for the management of both early and advanced tumors. The mechanisms of its antitumor action include generation of singlet oxygen and reactive oxygen species that directly damage tumor cells and tumor vasculature. A number of mechanisms seem to be involved in the protective responses to PDT that include activation of transcription factors, heat shock proteins, antioxidant enzymes and antiapoptotic pathways. Elucidation of these mechanisms might result in the design of more effective combination strategies to improve the antitumor efficacy of PDT. Using DNA microarray analysis to identify stress-related genes induced by Photofrin-mediated PDT in colon adenocarcinoma C-26 cells, we observed a marked induction of heme oxygenase-1 (HO-1). Induction of HO-1 with hemin or stable transfection of C-26 with a plasmid vector encoding HO-1 increased resistance of tumor cells to PDT-mediated cytotoxicity. On the other hand, zinc (II) protoporphyrin IX, an HO-1 inhibitor, markedly augmented PDT-mediated cytotoxicity towards C-26 and human ovarian carcinoma MDAH2774 cells. Neither bilirubin, biliverdin nor carbon monoxide, direct products of HO-1 catalysed heme degradation, was responsible for cytoprotection. Importantly, desferrioxamine, a potent iron chelator significantly potentiated cytotoxic effects of PDT. Altogether our results indicate that HO-1 is involved in an important protective mechanism against PDT-mediated phototoxicity and administration of HO-1 inhibitors might be an effective way to potentiate antitumor effectiveness of PDT.


Subject(s)
Heme Oxygenase-1/physiology , Photochemotherapy/adverse effects , Animals , Carbon Monoxide/chemistry , Carbon Monoxide/pharmacology , Chelating Agents/pharmacology , Dihematoporphyrin Ether/chemistry , Heme/chemistry , Heme Oxygenase-1/metabolism , Humans , Iron/pharmacology , Mice , Neoplasms/pathology , Oligonucleotide Array Sequence Analysis , Oxygen/metabolism , Reactive Oxygen Species
SELECTION OF CITATIONS
SEARCH DETAIL
...